Structure Therapeutics has the potential to have a best-in-class GLP-1 agonist drug for treatment of patients with obesity. Learn more on GPCR stock here.
Time for your weekly edition of the Defector Funbag. Got something on your mind? Email the Funbag. And buy Drew’s book, The Night The Lights Went Out, while you’re at it. Today, we’re talking about ...